



MEMO

To: CF111303 Principle Investigators
From: Enrico Colli, CSO, Chemo/Exeltis
Date: 28-May-2019
Re: FDA Approval of Slynd

CHEMO/Exeltis is very pleased to announce FDA's approval of Slynd (drospirinone) for prescription use in the United States. We wish to thank you and your team for the strong effort on our pivotal trial to bring this product to market.

We appreciate the hours spent working with source and electronic data to ensure accuracy and completeness and the time spent with subject to support each person through the 13 cycles of treatment. Only with you, your team and the volunteer subjects it is possible to bring Slynd to the US as an approved medication.

Thank you once again for all your support!

A handwritten signature in blue ink that reads "Enrico Colli".

Enrico Colli, MD
Chief Scientific Officer